SCHEMBL15024151

SCHEMBL15024151

CC(=O)C1CCCN1OC(N)C(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.35
DPP7 Q9UHL4 9/20 0.35
FAP Q12884 7/20 0.35
DPP8 Q6V1X1 6/20 0.35
DPP9 Q86TI2 5/20 0.35
PREP P48147 3/20 0.35
PITRM1 Q5JRX3 2/20 0.35
RAB9A P51151 1/20 0.34
CTSL P07711 1/20 0.32
CTSB P07858 1/20 0.32
CTSH P09668 1/20 0.32
CTSK P43235 1/20 0.32
ACE P12821 4/20 0.32
REN P00797 2/20 0.32
KDM4E B2RXH2 1/20 0.32
F2 P00734 1/20 0.32
LMNA P02545 1/20 0.32
LTA4H P09960 1/20 0.32
MAPT P10636 1/20 0.32
PEPD P12955 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15024154 0.87 ACE (0.36) DPP4DPP7FAPDPP8DPP9
SCHEMBL10056862 0.69 DPP4 (0.60) DPP4DPP7FAPDPP8DPP9
SCHEMBL23794392 0.69 DPP4 (0.60) DPP4DPP7FAPDPP8DPP9
SCHEMBL14865113 0.69 DPP4 (0.60) DPP4DPP7FAPDPP8DPP9
SCHEMBL10056861 0.68 DPP4 (0.58) DPP4DPP7FAPDPP8DPP9
SCHEMBL12285674 0.68 DPP4 (0.58) DPP4DPP7FAPDPP8DPP9
SCHEMBL10770001 0.67 HSD17B10 (0.33) LMNAHSD17B10
SCHEMBL57300 0.66 ACE (0.38) RAB9AACERENKDM4EF2
SCHEMBL16000536 0.66 ACE (0.38) RAB9AACERENKDM4EF2
SCHEMBL13233696 0.66 ACE (0.38) RAB9AACERENKDM4EF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029567-B2 Hypoglycemic compounds CADILA PHARMACEUTICALS LIMITED (IN) 2015-05-12 US disclosed
US-20130150578-A1 NOVEL HYPOGLYCEMIC COMPOUNDS CADILA PHARMACEUTICALS LIMITED (IN) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150578-A1 NOVEL HYPOGLYCEMIC COMPOUNDS GLP1R, GPR119, IAPP DPP4 10/4885DPP7 14/4885FAP 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.